Crossmark

Ruxolitinib is an effective salvage treatment for multidrug-resistant graft-versus-host disease after haploidentical allogeneic hematopoietic stem cell transplantation without posttransplant cyclophosphamide

Crossref DOI link: https://doi.org/10.1007/s00277-020-04273-2

Published Online: 2020-11-07

Published Print: 2021-01

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Zhao, Jiao-Yu

Liu, Si-Ning

Xu, Lan-Ping

Zhang, Xiao-Hui

Wang, Yu

Chen, Yu-Hong

Liu, Kai-Yan

Huang, Xiao-Jun

Mo, Xiao-Dong https://orcid.org/0000-0002-9881-7945
License Information

Text and Data Mining valid from 2020-11-07

Version of Record valid from 2020-11-07
More Information

Article History

Received: 27 November 2019

Accepted: 4 May 2020

First Online: 7 November 2020

Compliance with ethical standards

:

: The authors declare that they have no conflict of interest.

Document is current

Any future updates will be listed below